<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057689</url>
  </required_header>
  <id_info>
    <org_study_id>261081</org_study_id>
    <nct_id>NCT05057689</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Intranasal Dexmedetomidine, Fentanyl &amp; Midazolam in the Pediatric Emergency Room</brief_title>
  <official_title>A Double-blinded, Randomized Trial Comparing the Safety &amp; Efficacy of Intranasal Dexmedetomidine, Intranasal Fentanyl &amp; Intranasal Midazolam in the Pediatric Emergency Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that intranasal dexmedetomidine will provide significantly more effective&#xD;
      analgesia and anxiolysis for subjects undergoing a simple laceration repair when compared to&#xD;
      either intranasal fentanyl or intranasal midazolam.&#xD;
&#xD;
      Additional hypotheses include that there will be 1) no significant increase in adverse&#xD;
      effects between drugs and 2) significantly higher satisfaction rates for both subject&#xD;
      experience and ease of laceration repair based on structured, proceduralist feedback.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intranasal medications are rapidly gaining popularity as agents for analgesia and anxiolysis&#xD;
      in the pediatric hospital setting. One of the primary reasons for the popularity of&#xD;
      intranasal medications is ease of administration combined with favorable pharmacokinetics. It&#xD;
      has been well established that children identify venipuncture as one of the most painful and&#xD;
      anxiety-producing procedures during time spent in the hospital, and these experiences have&#xD;
      been shown to have a more lasting impact, producing increased anxiety and fear at subsequent&#xD;
      visits. Although oral and rectal administration of analgesics are also non-invasive,&#xD;
      bioavailability, time to onset, and half-lives are significantly longer with these routes of&#xD;
      administration in comparison to intranasal administration. Multiple studies have shown that&#xD;
      intranasal fentanyl, midazolam, and dexmedetomidine have similar pharmacokinetics to&#xD;
      intravenous preparations and reach adequate serum levels in both the blood and cerebrospinal&#xD;
      fluid. In the pediatric emergency room setting, intranasal fentanyl and midazolam have been&#xD;
      shown to provide effective analgesia and anxiolysis for a variety of settings, including pain&#xD;
      management (e.g. pain associated with long bone fractures, burns, incision and drainage) and&#xD;
      pre-procedural sedation/anxiolysis (e.g. radiological imaging).Numerous studies have examined&#xD;
      the safety and efficacy of intranasal fentanyl and midazolam, and several studies have&#xD;
      examined the efficacy of intranasal dexmedetomidine for non-painful procedural sedation. To&#xD;
      date, two studies have compared the use of intranasal dexmedetomidine and intranasal&#xD;
      midazolam or intranasal dexmedetomidine, intranasal fentanyl, and intranasal midazolam for&#xD;
      anxiolysis in painful procedural sedations. However, as of 2020, no previous studies have&#xD;
      compared the use of intranasal dexmedetomidine, intranasal fentanyl, and intranasal midazolam&#xD;
      for painful procedures in the pediatric emergency setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain using the Face, Legs, Activity, Cry, Consolability (FLACC) scale</measure>
    <time_frame>through the procedure, an average of 1 day</time_frame>
    <description>Analgesia in subjects undergoing simple laceration repair will be compared across the three investigational drug products (intranasal dexmedetomidine, intranasal fentanyl, and intranasal midazolam) using the FLACC scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety using the modified Yale Preoperative Anxiety Scale (mYPAS) behavior observation tool</measure>
    <time_frame>through the procedure, an average of 1 day</time_frame>
    <description>Anxiolysis in subjects undergoing simple laceration repair will be compared across the three investigational drug products (intranasal dexmedetomidine, intranasal fentanyl, and intranasal midazolam) using the modified Yale Preoperative Anxiety Scale (mYPAS) behavior observation tool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction rates for subject experience across the three study drugs based on parent/legally authorized representative (LAR) survey</measure>
    <time_frame>within 1 week of the laceration repair, average of 5 days</time_frame>
    <description>Parent/LAR will be asked to complete a follow-up survey so that parent/LAR can provide feedback on the level of satisfaction with the laceration repair experience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction rates for surgical repair across the three study drugs based on proceduralist survey</measure>
    <time_frame>within 1 week of the laceration repair, average of 5 days</time_frame>
    <description>Proceduralist will be asked to complete a follow-up survey to provide feedback on the level of satisfaction with the laceration repair experience.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Stress Disorder</condition>
  <condition>Anxiety</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Intranasal Dexmedetomidine (4 mcg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 200 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Fentanyl (2 mcg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 100 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Midazolam (5 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart. The maximum dose will be 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Dexmedetomidine (4 mcg/kg)</intervention_name>
    <description>Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 200 mcg.</description>
    <arm_group_label>Intranasal Dexmedetomidine (4 mcg/kg)</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Fentanyl (2 mcg/kg)</intervention_name>
    <description>Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 100 mcg.</description>
    <arm_group_label>Intranasal Fentanyl (2 mcg/kg)</arm_group_label>
    <other_name>Fentanyl Citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Midazolam (5 mg/kg)</intervention_name>
    <description>Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart prior to laceration repair. The maximum dose will be 10 mg.</description>
    <arm_group_label>Intranasal Midazolam (5 mg/kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary complaint of &quot;laceration&quot;&#xD;
&#xD;
          -  2 years to 6 years of age (inclusive)&#xD;
&#xD;
          -  Initial presentation at the Arkansas Children's Hospital (ACH) Emergency Department&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior allergic reaction to fentanyl or midazolam or dexmedetomidine&#xD;
&#xD;
          -  Prior major adverse reaction to fentanyl or midazolam (e.g. seizure-like activity,&#xD;
             paradoxical reaction, hallucinations)&#xD;
&#xD;
          -  Nasal injury/deformity&#xD;
&#xD;
          -  Potential for altered pain perception (e.g. autism, severe sensory-neural&#xD;
             disturbances)&#xD;
&#xD;
          -  History of adverse reaction to sedation/anesthesia&#xD;
&#xD;
          -  History of cardiac arrhythmia&#xD;
&#xD;
          -  History of liver dysfunction&#xD;
&#xD;
          -  Concurrent injuries that would necessitate higher levels of care (e.g. inpatient&#xD;
             admission, immediate evaluation in the operating room (OR), etc.)&#xD;
&#xD;
          -  Complex (multi-layer) lacerations or those requiring subspecialty consultation for&#xD;
             repair&#xD;
&#xD;
          -  American Society of Anesthesiology (ASA) score â‰¥ 3&#xD;
&#xD;
          -  Use of analgesics (with the exception of ibuprofen or acetaminophen) or anxiolytics in&#xD;
             the immediate pre-examination period (within 4 hours)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Chang, MD</last_name>
    <phone>501-364-1050</phone>
    <email>JChang3@uams.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan Chang, MD</last_name>
      <phone>501-364-1050</phone>
      <email>jchang3@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Stress Disorders, Traumatic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

